SYK Stock Recent News

Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.

xAI Holdings led performance, driven by rapid AI innovation, Grok 3 launch, and the strategic acquisition of X, enhancing data access and integration. Spotify delivered strong results with margin expansion, robust user growth despite price hikes, and record free cash flow, positioning it as a long-term streaming leader. Nvidia, Tesla, and Broadcom detracted due to market skepticism and macro concerns, but we remain confident in their long-term AI-driven growth prospects.

Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.

If you read Fundsmith's Owner's Manual, the influence of Warren Buffett on Terry Smith's hedge fund is plainly obvious. Smith references the Oracle of Omaha's wisdom and Berkshire Hathaway's success no fewer than six times in the 17-page document.

I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.

The Investment Committee kick off the week with their top picks. Don't miss it!

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.

Stryker Corporation (NYSE:SYK ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Preston Wells - Vice President, Chief Financial Officer Conference Call Participants Marcus Robert - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Vijay Kumar - Evercore ISI David Roman - Goldman Sachs Philip Chickering - Deutsche Bank Matthew Miksic - Barclays Patrick Wood - Morgan Stanley Shagun Singh - RBC Mike Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Danielle Antalffy - UBS Matt Taylor - Jefferies Operator Welcome to the First Quarter 2025 Stryker Earnings Call. My name is Luke and I'll be your operator for today's call.

Stryker beat Wall Street estimates for quarterly profit on Thursday, fueled by strong demand for its medical and surgical devices.